Across TCGA pan-cancer cohorts, ZNF627 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF627 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ZNF627 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF627 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL and UCEC are the cancer types where ZNF627 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.019	0.800	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.928	0.478	.022	16	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ZNF627 tumor-vs-normal RNA expression · all ZNF627 data types